PE20050880A1 - Proceso para reducir la cantidad de 14-hidroxicodeinona en una preparacion de clorhidrato de oxicodona - Google Patents

Proceso para reducir la cantidad de 14-hidroxicodeinona en una preparacion de clorhidrato de oxicodona

Info

Publication number
PE20050880A1
PE20050880A1 PE2005000361A PE2005000361A PE20050880A1 PE 20050880 A1 PE20050880 A1 PE 20050880A1 PE 2005000361 A PE2005000361 A PE 2005000361A PE 2005000361 A PE2005000361 A PE 2005000361A PE 20050880 A1 PE20050880 A1 PE 20050880A1
Authority
PE
Peru
Prior art keywords
oxycodone
hydroxycodeinone
composition
amount
hydrochloride
Prior art date
Application number
PE2005000361A
Other languages
English (en)
Spanish (es)
Inventor
Robert Chapman
Lonn S Rider
Qi Hong
Donald Kyle
Robert Kupper
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35124996&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20050880(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of PE20050880A1 publication Critical patent/PE20050880A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C07D489/04—Salts; Organic complexes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
PE2005000361A 2004-03-30 2005-03-29 Proceso para reducir la cantidad de 14-hidroxicodeinona en una preparacion de clorhidrato de oxicodona PE20050880A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US55749204P 2004-03-30 2004-03-30
US60153404P 2004-08-13 2004-08-13
US62007204P 2004-10-18 2004-10-18
US64862505P 2005-01-31 2005-01-31
US65177805P 2005-02-10 2005-02-10

Publications (1)

Publication Number Publication Date
PE20050880A1 true PE20050880A1 (es) 2005-11-16

Family

ID=35124996

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000361A PE20050880A1 (es) 2004-03-30 2005-03-29 Proceso para reducir la cantidad de 14-hidroxicodeinona en una preparacion de clorhidrato de oxicodona

Country Status (38)

Country Link
US (35) US7129248B2 (enExample)
EP (7) EP2311839A1 (enExample)
JP (8) JP4912294B2 (enExample)
KR (12) KR101410141B1 (enExample)
CN (5) CN102127086B (enExample)
AP (1) AP2232A (enExample)
AR (1) AR049012A1 (enExample)
AT (2) ATE501150T1 (enExample)
AU (2) AU2005230826C1 (enExample)
BR (1) BRPI0508758B8 (enExample)
CA (3) CA2913355C (enExample)
CR (2) CR8593A (enExample)
CY (5) CY1111487T1 (enExample)
DE (2) DE202005021371U1 (enExample)
DK (6) DK2426132T3 (enExample)
EA (1) EA013208B1 (enExample)
EC (1) ECSP066953A (enExample)
ES (6) ES2362282T5 (enExample)
FI (1) FI7843U1 (enExample)
HR (5) HRP20110425T4 (enExample)
HU (3) HUE029913T2 (enExample)
IL (8) IL178038A (enExample)
LT (2) LT2316837T (enExample)
MA (1) MA28492B1 (enExample)
ME (4) ME03068B (enExample)
MX (2) MX363228B (enExample)
MY (3) MY143205A (enExample)
NO (1) NO337669B1 (enExample)
NZ (3) NZ549430A (enExample)
PE (1) PE20050880A1 (enExample)
PL (5) PL2305683T3 (enExample)
PT (5) PT1730151E (enExample)
RS (5) RS53891B1 (enExample)
SG (3) SG10201406658VA (enExample)
SI (5) SI1730151T2 (enExample)
TW (3) TWI483944B (enExample)
WO (1) WO2005097801A1 (enExample)
ZA (1) ZA200607181B (enExample)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102004020220A1 (de) * 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
HRP20070456T3 (en) * 2003-08-06 2007-11-30 Grnenthal Gmbh Dosage form that is safeguarded from abuse
US20070048228A1 (en) * 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
TWI483944B (zh) * 2004-03-30 2015-05-11 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
DE102004032103A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102004032049A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
GB0421149D0 (en) * 2004-09-23 2004-10-27 Johnson Matthey Plc Preparation of oxycodone
US20080152595A1 (en) * 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE602006006558D1 (de) * 2005-03-04 2009-06-10 Euro Celtique Sa Verfahren zur verminderung von alpha, beta-ungesättigten ketonen in opioidzusammensetzungen
US20070082845A1 (en) * 2005-07-15 2007-04-12 The Penn State Research Foundation Ferritin as a therapeutic target in abnormal cells
KR20150041176A (ko) 2005-11-22 2015-04-15 콘드롤드 케미컬즈, 인크. 옥시코돈 및 다른 조성물에서 오염물질인 마이클 수용체 수준을 감소시키는 방법
US20070117826A1 (en) * 2005-11-23 2007-05-24 Forest Laboratories, Inc. Pharmaceutical formulations comprising ibuprofen, oxycodone, and 14-hydroxycodeinone
WO2007103105A2 (en) * 2006-03-02 2007-09-13 Mallinckrodt Inc. Processes for preparing morphinan-6-one products with low levels of alpha, beta-unsaturated ketone compounds
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
CA2674915C (en) * 2006-10-17 2015-06-30 Penick Corporation Process for preparing oxymorphone
US20080125592A1 (en) * 2006-10-17 2008-05-29 Penick Corporation Process for preparing oxymorphone, naltrexone, and buprenorphine
ES2392594T3 (es) * 2006-10-17 2012-12-12 Penick Corporation Procedimiento para preparar oximorfona
CN101652369A (zh) 2006-12-04 2010-02-17 诺拉姆科有限公司 减少羟考酮碱中杂质的方法
EP2121699B1 (en) 2006-12-04 2012-09-19 Noramco, Inc. Process for preparing oxycodone having reduced levels of 14-hydroxycodeinone
GB0624880D0 (en) * 2006-12-14 2007-01-24 Johnson Matthey Plc Improved method for making analgesics
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
EP2125824B2 (en) * 2007-03-23 2023-11-15 Mallinckrodt LLC Improved preparation of oxymorphone from oripavine
AU2008241528B2 (en) * 2007-04-16 2013-07-04 Mallinckrodt Llc Novel opiate reduction utilizing catalytic hydrogen transfer reaction
KR101616246B1 (ko) 2008-01-25 2016-05-02 그뤼넨탈 게엠베하 약제학적 투여형
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
AU2009223061B2 (en) * 2008-03-11 2014-10-09 Depomed Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
PL2273983T3 (pl) 2008-05-09 2017-01-31 Grünenthal GmbH Sposób wytwarzania pośredniego preparatu proszkowego i końcowej stałej postaci dawkowania z zastosowaniem etapu zestalania rozpyłowego
US20110165248A1 (en) * 2008-09-18 2011-07-07 Meridith Lee Machonis Pharmaceutical dosage forms comprising poly(e-caprolactone)
PE20121067A1 (es) * 2009-07-22 2012-09-05 Gruenenthal Chemie Forma de dosificacion de liberacion controlada extruida por fusion en caliente
PE20120631A1 (es) 2009-07-22 2012-06-06 Gruenenthal Chemie Forma de dosificacion resistente a la manipulacion para opioides sensibles a la oxidacion
KR20120059582A (ko) * 2009-08-31 2012-06-08 데포메드 인코퍼레이티드 아세트아미노펜의 속방성 및 서방성을 위한 위 체류 약제학적 조성물
ES2569925T3 (es) 2009-09-30 2016-05-13 Acura Pharmaceuticals, Inc. Métodos y composiciones de disuasión del abuso
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
ES2606227T3 (es) * 2010-02-03 2017-03-23 Grünenthal GmbH Preparación de una composición farmacéutica en polvo mediante una extrusora
EP2377866B1 (en) 2010-03-23 2014-02-26 Siegfried AG Preparation of low impurity opiates in a continuous flow reactor
AP3441A (en) 2010-05-10 2015-10-31 Euro Celtique Sa Pharmaceutical compositions comprising hydromorphone and naloxone
US9993433B2 (en) 2010-05-10 2018-06-12 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
AU2011252041B2 (en) 2010-05-10 2014-04-03 Euro-Celtique S.A. Combination of active loaded granules with additional actives
CA2802295C (en) 2010-06-11 2016-09-20 Rhodes Technologies Transition metal-catalyzed processes for the preparation of n-allyl compounds and use thereof
TWI471289B (zh) 2010-06-11 2015-02-01 Rhodes Technologies 使三級胺進行ｎ－脫烷反應之方法
AU2011274361B2 (en) * 2010-07-02 2014-09-18 Macfarlan Smith Limited Process for the synthesis and purification of oxycodone
US8912781B2 (en) * 2010-07-30 2014-12-16 Cirrus Logic, Inc. Integrated circuit switching power supply controller with selectable buck mode operation
WO2012028318A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polymer
ES2486791T3 (es) 2010-09-02 2014-08-19 Grünenthal GmbH Forma de dosificación resistente a la manipulación que comprende una sal inorgánica
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
SI2736495T1 (sl) 2011-07-29 2017-12-29 Gruenenthal Gmbh Tableta, odporna proti zlorabi, ki zagotavlja takojšnje sproščanje zdravila
PE20141650A1 (es) 2011-07-29 2014-11-22 Gruenenthal Chemie Tableta a prueba de alteracion que proporciona liberacion inmediata del farmaco
WO2013034273A1 (en) * 2011-09-05 2013-03-14 Siegfried Ltd. Kit comprising a packaging material and a solid pharmaceutical or nutraceutical product contained in the packaging material
ES2583132T3 (es) 2011-09-16 2016-09-19 Purdue Pharma L.P. Formulaciones de liberación inmediata resistentes a alteración
CA2847611A1 (en) 2011-09-16 2013-03-21 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
TW201336529A (zh) 2011-12-09 2013-09-16 Purdue Pharma Lp 包含聚（ε－己內酯）和聚氧化乙烯之藥物劑量型
EP2819656A1 (en) 2012-02-28 2015-01-07 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
EP2819653B1 (en) 2012-03-02 2017-01-11 Rhodes Pharmaceuticals L.P. Tamper resistant immediate release formulations
CA2868413C (en) 2012-04-17 2021-07-20 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
RS57913B1 (sr) 2012-04-18 2019-01-31 Gruenenthal Gmbh Farmaceutske dozne forme otporne na neovlašćenu upotrebu i naglo oslobađanje celokupne doze
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CA2877774C (en) 2012-07-12 2017-07-18 Mallinckrodt Llc Extended release, abuse deterrent pharmaceutical compositions
NZ715111A (en) * 2012-07-16 2016-12-23 Rhodes Technologies Process for improved opioid synthesis
UA117225C2 (uk) * 2012-07-16 2018-07-10 Родес Текнолоджіс Спосіб покращеного синтезу опіоїду
WO2014022733A1 (en) 2012-08-03 2014-02-06 Johnson Matthey Public Limited Company A method for preparing oxycodone
MX366159B (es) 2012-11-30 2019-07-01 Acura Pharmaceuticals Inc Liberacion autorregulada de ingrediente farmaceutico activo.
JP6208261B2 (ja) 2013-02-05 2017-10-04 パーデュー、ファーマ、リミテッド、パートナーシップＰｕｒｄｕｅ Ｐｈａｒｍａ Ｌ．Ｐ． タンパリング抵抗性医薬製剤
US9770710B2 (en) 2013-02-20 2017-09-26 University Of Washington Through Its Center For Commercialization Hydrogenation and disproportionation catalysis
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
JP6445537B2 (ja) 2013-05-29 2018-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング １個または複数の粒子を含有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
US10624862B2 (en) 2013-07-12 2020-04-21 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
GB201313211D0 (en) 2013-07-24 2013-09-04 Cambrex Karlskoga Ab New process
CN105452253A (zh) 2013-08-02 2016-03-30 庄信万丰股份有限公司 用于制备氢羟吗啡酮的方法
GB201313915D0 (en) * 2013-08-02 2013-09-18 Johnson Matthey Plc Process
MX2016005187A (es) 2013-11-07 2016-08-08 Mallinckrodt Llc Produccion de 6-hidroxi morfinanos sin el aislamiento de intermediarios.
BR112016009749A8 (pt) 2013-11-13 2018-01-30 Euro Celtique Sa hidromorfona e naloxona para tratamento de dor e síndrome de disfunção intestinal opioide
AU2014356581C1 (en) 2013-11-26 2020-05-28 Grunenthal Gmbh Preparation of a powdery pharmaceutical composition by means of cryo-milling
US10227354B2 (en) 2013-12-18 2019-03-12 Cody Laboratories, Inc. Conversion of oxycodone base to oxycodone hydrochloride
US9062062B1 (en) 2013-12-18 2015-06-23 Cody Laboratories, Inc. Synthesis of oxycodone hydrochloride
US8846923B1 (en) 2013-12-18 2014-09-30 Cody Laboratories, Inc. Preparation of 14-hydroxycodeinone sulfate
KR101868724B1 (ko) 2014-01-15 2018-06-18 로드스 테크놀로지즈 개선된 옥시모르폰 합성을 위한 방법
KR101868723B1 (ko) 2014-01-15 2018-06-18 로드스 테크놀로지즈 개선된 옥시코돈 합성을 위한 방법
CA2938699A1 (en) 2014-02-05 2015-08-13 Kashiv Pharma Llc Abuse-resistant drug formulations with built-in overdose protection
EP3122336A4 (en) 2014-03-26 2017-10-25 Sun Pharma Advanced Research Company Ltd Abuse deterrent immediate release biphasic matrix solid dosage form
AU2015261060A1 (en) 2014-05-12 2016-11-03 Grunenthal Gmbh Tamper resistant immediate release capsule formulation comprising Tapentadol
EP3148512A1 (en) 2014-05-26 2017-04-05 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
MA40332A (fr) 2014-07-09 2021-04-28 Rhodes Tech Réduction des niveaux de cétone alpha, beta-insaturée dans des compositions de dérivés de morphinane
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
US20160052932A1 (en) * 2014-08-25 2016-02-25 Johnson Matthey Public Limited Company Processes for Making Opioids Including 14-Hydroxycodeinone and 14-hydroxymorphinone
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
CN105777766B (zh) * 2014-12-15 2017-11-24 北大方正集团有限公司 Delta‑7溴甲纳曲酮的制备方法
US9918979B2 (en) * 2015-01-29 2018-03-20 Johnson Matthey Public Limited Company Process of preparing low ABUK oxymorphone hydrochloride
EP3285745A1 (en) 2015-04-24 2018-02-28 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
GB201513203D0 (en) 2015-07-27 2015-09-09 Cambrex Charles City Inc New process
US11103581B2 (en) 2015-08-31 2021-08-31 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
AU2016319203A1 (en) 2015-09-10 2018-02-22 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
US20180104236A1 (en) 2016-09-26 2018-04-19 Euro-Celtique S. A. Methods of treatment comprising administering a high daily dose of oxycodone and naloxone in a 2:1 weight ratio
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
US10941154B2 (en) 2017-06-20 2021-03-09 Johnson Matthey Public Limited Company Hydrogenation process for preparing oxycodone hydrochloride from 14-hydroxycodeinone
WO2019006404A1 (en) 2017-06-30 2019-01-03 Purdue Pharma L.P. METHOD OF TREATMENT AND DOSAGE FORMS
CN110330500B (zh) * 2019-07-12 2021-11-23 宜昌人福药业有限责任公司 一种6β-羟基-7,8-二氢-吗啡衍生物的立体选择性合成方法
CN113009060B (zh) * 2021-02-24 2022-10-21 西南药业股份有限公司 高效液相色谱法测定盐酸羟考酮含量的方法

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US100000A (en) * 1870-02-22 Improved sun-bonnet for horses
US105553A (en) 1870-07-19 Improvement in kettle for melting, mixing, and casting metals
US420098A (en) * 1890-01-28 Mowing-machine
US1468805A (en) 1923-09-25 Htabtin ereund
DE296916C (enExample) *
DE286431C (enExample)
US1485673A (en) * 1924-03-04 Ministrator
US710223A (en) * 1901-06-10 1902-09-30 Thew Automatic Shovel Company Power-shovel.
SU64699A1 (ru) 1944-01-26 1944-11-30 А.И. Лютенберг Способ получени сол нокислого дигидрооксикодеинона
ES212554A1 (es) 1953-12-01 1954-08-16 Casanovas Albajes Cesar Un procedimiento para la obtención de un vidrio orgánico
US2772270A (en) 1954-10-21 1956-11-27 M J Lewenstein 14-hydroxymorphinone and 8, 14-dihydroxydihydromorphinone
US2806033A (en) 1955-08-03 1957-09-10 Lewenstein Morphine derivative
US3173878A (en) * 1960-02-26 1965-03-16 Ibm Process of making microcapsules
US3173876A (en) 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (enExample) 1960-11-29
US3276586A (en) 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US3916898A (en) 1964-05-20 1975-11-04 Searle & Co Administration of medicaments and the like
NL6714885A (enExample) 1967-11-02 1969-05-06
US3541006A (en) 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3905981A (en) 1973-10-12 1975-09-16 Research Corp N-dealkylation of tertiary amines
US3894026A (en) 1973-10-16 1975-07-08 Merck & Co Inc Production of thebaine
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US3984026A (en) * 1976-03-26 1976-10-05 Shoup Russel W Combined can opening and sealing device
US4045440A (en) 1976-09-16 1977-08-30 The United States Of America As Represented By The Department Of Health, Education And Welfare Method of producing thebaine from codeine and oripavine from morphine
US4285987A (en) 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4272540A (en) 1979-04-24 1981-06-09 Sisa, Incorporated 14-Methoxymorphinan-6-one compounds and therapeutic methods of treating pain and drug dependence with them
US4370333A (en) 1981-06-29 1983-01-25 Sisa, Incorporated 17-Cyclopropylmethyl-3-hydroxy-14-methoxy 7α-methyl-morphinan-6-one and therapeutic method of treating pain with it
US4795813A (en) 1981-08-17 1989-01-03 The Florida Board Of Regents On Behalf Of The Florida State University Synthesis of derivatives of codeine and other 3-O-alkylmorphines
US4639520A (en) 1984-03-27 1987-01-27 Mallinckrodt, Inc. Preparation of 14-hydroxy-N-ethoxy-carbonyl-norcodeinone
US5112975A (en) 1984-03-27 1992-05-12 Mallinckrodt Specialty Chemicals Company Preparation of noroxymorphone from morphine
US4861598A (en) 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4810699A (en) 1987-02-20 1989-03-07 American Home Products Corporation Substituted 1,3,4,9-tetrahydropyrano[3,4,-b]indole-1-acetic acids, pharmaceutical compositions containing them, and methods for treating inflammatory conditions and for analgesic purposes using them
US4810669A (en) * 1987-07-07 1989-03-07 Oki Electric Industry Co., Ltd. Method of fabricating a semiconductor device
DE3812567A1 (de) 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
HU208633B (en) 1991-02-04 1993-12-28 Alkaloida Vegyeszeti Gyar Process for production of analgetic compositions as applicable for blocking of opioid-binding spaces /2-receptors/ causing respiration depression
US5215758A (en) 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
US5656295A (en) 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5472712A (en) 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5273760A (en) 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5286493A (en) 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5324351A (en) 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
JP3433871B2 (ja) * 1996-01-26 2003-08-04 株式会社デンソー 集積化半導体歪みセンサ及びその製造方法
ES2334768T1 (es) 1996-06-26 2010-03-16 Board Of Regents, The University Of Texas System Formulacion farmaceutica extruible de liberacion controlada.
US5869669A (en) 1996-07-26 1999-02-09 Penick Corporation Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
ES2121554B1 (es) * 1996-12-23 1999-06-16 Univ Santiago Compostela Procedimiento de obtencion de 14-hidroximofinonas mediante fotooxidac ion de alcaloides morfinicos con sistema alcoxidienico en el anillo c.
GB9713703D0 (en) * 1997-06-30 1997-09-03 Johnson Matthey Plc Preparation of opiates
GB9717629D0 (en) 1997-08-21 1997-10-22 Johnson Matthey Plc Removal of residual organic solvents
US6710223B1 (en) * 1997-09-10 2004-03-23 The Procter & Gamble Company Method for improving skin condition
GB9805516D0 (en) 1998-03-17 1998-05-13 Johnson Matthey Plc Preparation of opiates
US6454970B1 (en) * 1998-10-14 2002-09-24 Amic Ab And Gyros Ab Matrix, method of producing and using the matrix and machine including the matrix
US6177567B1 (en) * 1999-10-15 2001-01-23 Boehringer Ingelheim Chemicals, Inc. Method for preparing oxycodone
US6284769B1 (en) * 1999-12-03 2001-09-04 The Board Of Trustees Of The University Of Illinois Nonpeptide kappa opioid receptor antagonists
US6133132A (en) * 2000-01-20 2000-10-17 Advanced Micro Devices, Inc. Method for controlling transistor spacer width
ES2539904T3 (es) * 2000-02-08 2015-07-07 Euro-Celtique S.A. Formulaciones orales de agonistas opioides resistentes a manipulaciones indebidas
WO2001092188A1 (en) 2000-05-29 2001-12-06 Shionogi & Co., Ltd. Method for labeling with tritium
US7200357B2 (en) * 2000-10-20 2007-04-03 Universal Electronics Inc. Automotive storage and playback device and method for using the same
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
NZ529661A (en) * 2001-06-05 2006-03-31 Control Delivery Systems Sustained-release analgesic compounds
AU2002314968B2 (en) 2001-06-08 2006-12-07 Endo Pharmaceuticals, Inc. Controlled release dosage forms using acrylic polymer, and process for making the same
JP4256259B2 (ja) 2001-07-18 2009-04-22 ユーロ−セルティーク エス．エイ． オキシコドン及びナロキソンの医薬配合物
AU2003235678A1 (en) * 2002-01-15 2003-07-30 Aerogen, Inc. Systems and methods for clearing aerosols from the effective anatomic dead space
US7790215B2 (en) * 2002-03-26 2010-09-07 Purdue Pharma Lp Sustained-release gel coated compositions
ATE419830T1 (de) * 2002-04-29 2009-01-15 Alza Corp Methoden und darreichungsformen zur kontrollierten freisetzung von oxykodon
WO2003101132A1 (en) * 2002-05-27 2003-12-04 Ntt Docomo, Inc. Mobile communication system, transmission station, reception station, relay station, communication path deciding method, and communication path deciding program
MXPA04012021A (es) 2002-05-31 2005-08-16 Johnson & Johnson Formas de dosis y composiciones para la administracion osmotica de dosis variables de oxicodona.
US20040058946A1 (en) * 2002-07-05 2004-03-25 Buchwald Stephen L. Abuse-resistant prodrugs of oxycodone and other pharmaceuticals
AU2003247876B2 (en) * 2002-07-05 2006-10-05 Collegium Pharmaceutical, Inc Abuse-deterrent pharmaceutical compositions of opiods and other drugs
CN100439373C (zh) * 2002-08-15 2008-12-03 诺拉姆科有限公司 羟考酮盐酸盐多晶型物
WO2004045551A2 (en) 2002-11-15 2004-06-03 Branded Products For The Future Pharmaceutical composition
CA2507851A1 (en) * 2002-11-29 2004-06-17 Forest Laboratories, Inc. Combination of ibuprofen and oxycodone for acute pain relief
FR2850576B1 (fr) * 2003-02-05 2007-03-23 Ethypharm Sa Composition comprenant un melange de principes actifs, et procede de preparation
DE602004024963D1 (de) 2003-03-13 2010-02-25 Controlled Chemicals Inc Oxycodon- konjugate mit niedrigerem missbrauch- potential und ausgedehnter tätigkeitsdauer
US6864370B1 (en) * 2003-06-05 2005-03-08 Zhaiwei Lin Process for manufacturing oxycodone
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
TWI483944B (zh) 2004-03-30 2015-05-11 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
US20070172958A1 (en) * 2004-03-30 2007-07-26 Euro-Celtique S.A. Methods for detecting 14-hydroxy codeinone and codeinone
US20050226929A1 (en) 2004-04-12 2005-10-13 Jianbo Xie Controlled release opioid analgesic formulation
JP5329083B2 (ja) 2004-06-25 2013-10-30 テッセラ，インコーポレイテッド ポストおよびパッドを有する部品
GB0421149D0 (en) 2004-09-23 2004-10-27 Johnson Matthey Plc Preparation of oxycodone
DE602006006558D1 (de) 2005-03-04 2009-06-10 Euro Celtique Sa Verfahren zur verminderung von alpha, beta-ungesättigten ketonen in opioidzusammensetzungen
ES2357216T3 (es) 2005-06-16 2011-04-20 Mallinckrodt, Inc. Una ruta de síntesis de 14-hidroxil-opiáceos a través de 1-halo-tebaína o análogos.
KR20150041176A (ko) 2005-11-22 2015-04-15 콘드롤드 케미컬즈, 인크. 옥시코돈 및 다른 조성물에서 오염물질인 마이클 수용체 수준을 감소시키는 방법
US20070117826A1 (en) * 2005-11-23 2007-05-24 Forest Laboratories, Inc. Pharmaceutical formulations comprising ibuprofen, oxycodone, and 14-hydroxycodeinone
WO2007103105A2 (en) 2006-03-02 2007-09-13 Mallinckrodt Inc. Processes for preparing morphinan-6-one products with low levels of alpha, beta-unsaturated ketone compounds
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
EP2121699B1 (en) * 2006-12-04 2012-09-19 Noramco, Inc. Process for preparing oxycodone having reduced levels of 14-hydroxycodeinone
CN101652369A (zh) 2006-12-04 2010-02-17 诺拉姆科有限公司 减少羟考酮碱中杂质的方法
GB2450691A (en) 2007-07-02 2009-01-07 Alpharma Aps One-pot preparation of oxycodone from thebaine
AU2011274361B2 (en) * 2010-07-02 2014-09-18 Macfarlan Smith Limited Process for the synthesis and purification of oxycodone
US9062062B1 (en) * 2013-12-18 2015-06-23 Cody Laboratories, Inc. Synthesis of oxycodone hydrochloride

Also Published As

Publication number Publication date
HRP20160223T1 (hr) 2016-03-25
US9522919B2 (en) 2016-12-20
PL2319846T3 (pl) 2016-12-30
PL1730151T3 (pl) 2011-08-31
ZA200607181B (en) 2007-11-28
US20150258086A1 (en) 2015-09-17
PT2426132E (pt) 2016-03-31
SI2305683T1 (sl) 2015-04-30
MY172063A (en) 2019-11-13
US7674799B2 (en) 2010-03-09
EP2311839A1 (en) 2011-04-20
BRPI0508758A (pt) 2007-08-28
CY1117228T1 (el) 2017-04-05
KR20140021716A (ko) 2014-02-20
US12060361B2 (en) 2024-08-13
CA2774121A1 (en) 2005-10-20
KR20140133615A (ko) 2014-11-19
CN1960994A (zh) 2007-05-09
FI7843U1 (fi) 2008-04-28
ES2665287T3 (es) 2018-04-25
US20150265597A1 (en) 2015-09-24
EP2319846A1 (en) 2011-05-11
EP2305683B1 (en) 2015-01-28
KR20070022033A (ko) 2007-02-23
US20200062772A1 (en) 2020-02-27
US11384091B2 (en) 2022-07-12
CN101812065B (zh) 2012-03-28
US20160251364A1 (en) 2016-09-01
US7674798B2 (en) 2010-03-09
HUE029913T2 (en) 2017-04-28
IL235298A (en) 2016-11-30
CY1116327T1 (el) 2017-02-08
HK1155729A1 (en) 2012-05-25
EP2314589A1 (en) 2011-04-27
MA28492B1 (fr) 2007-03-01
DK2305683T3 (en) 2015-04-07
DK1730151T4 (da) 2020-10-19
IL178038A0 (en) 2006-12-31
HRP20180407T1 (hr) 2018-04-20
AU2005230826A1 (en) 2005-10-20
IL213888A0 (en) 2011-07-31
PL1730151T5 (pl) 2023-09-18
IL214050A0 (en) 2011-08-31
IL214050A (en) 2013-09-30
US10259819B2 (en) 2019-04-16
US9073933B2 (en) 2015-07-07
US20180022754A1 (en) 2018-01-25
SI1730151T2 (sl) 2021-03-31
EP1730151A4 (en) 2007-05-23
EA200601520A1 (ru) 2007-02-27
LT2314589T (lt) 2023-06-12
AP2232A (en) 2011-05-04
CN102127086B (zh) 2013-11-27
TW201509943A (zh) 2015-03-16
KR101410141B1 (ko) 2014-06-25
RS54941B1 (sr) 2016-11-30
PL2316837T3 (pl) 2018-07-31
MY154985A (en) 2015-08-28
IL213889A (en) 2012-06-28
HUE028233T2 (en) 2016-12-28
JP2012072162A (ja) 2012-04-12
US20210094963A1 (en) 2021-04-01
US20190161492A1 (en) 2019-05-30
KR20090104145A (ko) 2009-10-05
SI2316837T1 (en) 2018-05-31
ATE501150T1 (de) 2011-03-15
US20230365578A1 (en) 2023-11-16
MY143205A (en) 2011-03-31
BRPI0508758B1 (pt) 2018-10-09
MX2020008878A (es) 2020-11-09
AU2009200335B2 (en) 2011-07-28
US20100152449A1 (en) 2010-06-17
CN102838607A (zh) 2012-12-26
CR20110376A (es) 2011-09-19
US10407434B2 (en) 2019-09-10
KR20150046393A (ko) 2015-04-29
US20070117830A1 (en) 2007-05-24
SG170735A1 (en) 2011-05-30
PT2319846T (pt) 2016-08-12
EP2316837A1 (en) 2011-05-04
JP2014139205A (ja) 2014-07-31
DE202005021371U1 (de) 2007-10-25
US20200087316A1 (en) 2020-03-19
KR20120046309A (ko) 2012-05-09
ES2362282T3 (es) 2011-06-30
ES2362282T5 (es) 2021-06-24
DK200700214U1 (da) 2007-11-23
SI1730151T1 (sl) 2011-06-30
EP2305683A1 (en) 2011-04-06
CA2557845A1 (en) 2005-10-20
US20160251365A1 (en) 2016-09-01
CN102838607B (zh) 2016-08-03
CA2913355A1 (en) 2005-10-20
US20150265598A1 (en) 2015-09-24
NZ549430A (en) 2010-05-28
CN101812065A (zh) 2010-08-25
CY1111487T1 (el) 2015-08-05
CA2913355C (en) 2021-04-20
NO20064935L (no) 2006-12-18
CN102887903A (zh) 2013-01-23
US9777011B2 (en) 2017-10-03
EP1730151A1 (en) 2006-12-13
US20070179169A1 (en) 2007-08-02
RS53891B1 (sr) 2015-08-31
JP2007531756A (ja) 2007-11-08
ME03068B (me) 2019-01-20
DK2319846T3 (en) 2016-08-15
CR8593A (es) 2007-07-19
US8822687B2 (en) 2014-09-02
US7674800B2 (en) 2010-03-09
RS51693B (sr) 2011-10-31
ES2938727T3 (es) 2023-04-14
KR101200700B1 (ko) 2012-11-13
IL213891A0 (en) 2011-07-31
IL241117A0 (en) 2015-11-30
JP4912294B2 (ja) 2012-04-11
CY1120171T1 (el) 2018-12-12
IL213890A (en) 2015-10-29
RS57000B1 (sr) 2018-05-31
DK2316837T3 (en) 2018-04-16
KR100993911B1 (ko) 2010-11-11
US20110207762A1 (en) 2011-08-25
HUE036451T2 (hu) 2018-07-30
KR20200000499A (ko) 2020-01-02
PT1730151E (pt) 2011-06-01
CN102127086A (zh) 2011-07-20
SG170736A1 (en) 2011-05-30
AU2009200335A1 (en) 2009-02-26
US20060173029A1 (en) 2006-08-03
EP2319846B1 (en) 2016-05-04
TW200540177A (en) 2005-12-16
US20160250205A1 (en) 2016-09-01
US20050222188A1 (en) 2005-10-06
US20160250204A1 (en) 2016-09-01
US7129248B2 (en) 2006-10-31
HRP20160885T1 (hr) 2016-09-23
US20210198268A1 (en) 2021-07-01
US20070117829A1 (en) 2007-05-24
JP5543991B2 (ja) 2014-07-09
TWI365880B (en) 2012-06-11
ES2535618T3 (es) 2015-05-13
KR20180088505A (ko) 2018-08-03
HK1155728A1 (en) 2012-05-25
KR20130020962A (ko) 2013-03-04
US20160175300A1 (en) 2016-06-23
EP2305683B8 (en) 2015-03-04
JP2015187134A (ja) 2015-10-29
DK1730151T3 (da) 2011-06-20
US20160185790A1 (en) 2016-06-30
ME02411B (me) 2016-09-20
WO2005097801A1 (en) 2005-10-20
AP2006003738A0 (en) 2006-10-31
HRP20110425T4 (hr) 2020-11-27
DK200700214U3 (da) 2008-02-08
US10696684B2 (en) 2020-06-30
US20160176888A1 (en) 2016-06-23
EA013208B1 (ru) 2010-04-30
IL178038A (en) 2015-10-29
US20160264588A1 (en) 2016-09-15
EP2316837B1 (en) 2018-01-10
ES2585576T3 (es) 2016-10-06
IL213890A0 (en) 2011-07-31
AU2005230826B2 (en) 2008-11-06
AT9952U1 (de) 2008-06-15
JP2012188439A (ja) 2012-10-04
LT2316837T (lt) 2018-04-10
IL241117B (en) 2020-06-30
US7683072B2 (en) 2010-03-23
US20160175298A1 (en) 2016-06-23
NO337669B1 (no) 2016-05-30
EP1730151B2 (en) 2020-09-16
MX363228B (es) 2019-03-15
US20070117831A1 (en) 2007-05-24
EP1730151B1 (en) 2011-03-09
AU2005230826C1 (en) 2014-10-16
ME02482B (me) 2017-02-20
ME01299B (me) 2011-10-31
US20130005977A1 (en) 2013-01-03
CN1960994B (zh) 2012-09-05
CY1117841T1 (el) 2017-05-17
PT2305683E (pt) 2015-05-18
PL2305683T3 (pl) 2015-07-31
HK1098745A1 (en) 2007-07-27
DE602005026786D1 (de) 2011-04-21
HRP20110425T1 (en) 2011-07-31
FIU20070284U0 (fi) 2007-07-04
SI2319846T1 (sl) 2016-08-31
RS51693B2 (sr) 2021-02-26
JP5118223B2 (ja) 2013-01-16
IL213889A0 (en) 2011-07-31
DK2426132T3 (en) 2016-04-04
EP2426132B1 (en) 2016-01-13
US20160176889A1 (en) 2016-06-23
RS54598B1 (sr) 2016-08-31
NZ602862A (en) 2014-01-31
US11236098B2 (en) 2022-02-01
TW201231469A (en) 2012-08-01
US20160251363A1 (en) 2016-09-01
JP5378486B2 (ja) 2013-12-25
ES2566363T3 (es) 2016-04-12
HRP20150358T1 (hr) 2015-05-08
US20160175299A1 (en) 2016-06-23
JP2017125052A (ja) 2017-07-20
EP2314589B1 (en) 2022-12-28
ECSP066953A (es) 2006-12-20
PT2316837T (pt) 2018-04-02
PL2426132T3 (pl) 2016-06-30
CA2557845C (en) 2013-10-01
BRPI0508758B8 (pt) 2021-05-25
KR20110110377A (ko) 2011-10-06
CA2774121C (en) 2016-02-16
AR049012A1 (es) 2006-06-21
JP6503392B2 (ja) 2019-04-17
US20160185788A1 (en) 2016-06-30
EP2426132A1 (en) 2012-03-07
KR100930730B1 (ko) 2009-12-09
EP2305683B2 (en) 2024-09-11
JP2018184462A (ja) 2018-11-22
JP2011157370A (ja) 2011-08-18
TWI483944B (zh) 2015-05-11
SI2426132T1 (sl) 2016-04-29
SG10201406658VA (en) 2014-12-30
US20230159548A1 (en) 2023-05-25
KR20120106784A (ko) 2012-09-26
CN102887903B (zh) 2016-01-27
KR20100069719A (ko) 2010-06-24
NZ601326A (en) 2013-10-25
US20160185789A1 (en) 2016-06-30
US10689389B2 (en) 2020-06-23
US20090227615A1 (en) 2009-09-10

Similar Documents

Publication Publication Date Title
PE20050880A1 (es) Proceso para reducir la cantidad de 14-hidroxicodeinona en una preparacion de clorhidrato de oxicodona
EP1894887A3 (de) Verfahren zur Aufarbeitung einer Ätzmischung, die bei der Herstellung von hochreinem Silizium anfällt
CO6670555A2 (es) Método para recuperar oro por extracción con solvente
BRPI0401876A (pt) Processo para recuperação de catalisador de metal de um licor mãe, corrente de impurezas orgânicas com alto ponto de ebulição, corrente rica em solvente, processo para produção de uma corrente de licor mãe superconcentrado, e, composição
MY170077A (en) Lactic acid extraction
JP2006291352A5 (enExample)
RU2012137266A (ru) Способ получения водного потока при получении эталона
CN102372385A (zh) 硫酸铜回收方法及硫酸铜回收装置
RU2010133160A (ru) Способ синтеза тетрагидробиоптерина
JOP20210055A1 (ar) عملية لتنقية وتركيز العناصر الأرضية النادرة من الجبس الفوسفوري
DE602005000334D1 (de) Verfahren zur herstellung von oxycodon
ATE338016T1 (de) Verfahren zur reinigung von hexafluor-1,3- butadien
MX2010005124A (es) Procedimiento de preparacion de compuestos morfinicos.
PE20050001A1 (es) Metodo y equipo para purificar una solucion de extraccion de un arrastre acuoso e impurezas
EA200970644A1 (ru) Способ и устройство для извлечения металла и отделения мышьяка от мышьяксодержащего раствора
CO6170353A2 (es) Metodo y aparato para remover arsenico de una solucion
TW200510571A (en) High purity copper sulfate and method for production thereof
JP4552941B2 (ja) アニリンの精製方法および製造方法
ES2189764T3 (es) Proceso para la separacion y purificacion de una mezcla acuosa que tiene como componentes principales acido acetico y acido formico.
BRPI0411925A (pt) processo para separação e recuperação de ácido 3-hidroxipropiÈnico e ácido acrìlico
RU2005109425A (ru) Способ экстракции растворителем
AR047320A1 (es) Proceso de extraccion para remocion de impurezas de una corriente de purga oxidante en la sintesis de acido carboxilico
CN1123825A (zh) 一种石油馏分油氨醇脱酸工艺
MX2021007012A (es) Recuperación de valores de oro y plata de alimentos mediante extracción asistida por ultrasonido.
MX2008003249A (es) Mejora al proceso de lixiviacion y recuperacion de plata y oro con soluciones de tiourea electro-oxidada.

Legal Events

Date Code Title Description
FG Grant, registration